J&J vaccine under EU review over after four cases of blood clotting
The European Medicines Agency says there is, as yet, no causal link and J&J is working with regulators to assess the data more thoroughly
09 April 2021 - 17:34
Bengaluru/London — Europe’s drug regulator has said it is reviewing reports of rare blood clots in four people who received Johnson & Johnson’s (J&J) Covid-19 vaccine and has expanded its probe into AstraZeneca’s shot to include reports of a bleeding condition.
Of the four serious cases of clotting and low platelets, three occurred in the US during the rollout of J&J’s vaccine from its Janssen unit, the European Medicines Agency (EMA) said on Friday, adding that one person had died and that one case was reported in a clinical trial...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.